# Insilico Medicine

> Source: https://aiwiki.ai/wiki/insilico_medicine
> Updated: 2026-06-28
> Categories: AI Companies, Drug Discovery, Healthcare AI
> From AI Wiki (https://aiwiki.ai), a free encyclopedia of artificial intelligence. Quote with attribution.

**Insilico Medicine** is a clinical-stage biotechnology company that uses [generative AI](/wiki/generative_ai) to discover disease targets and design small-molecule drugs end to end. Founded in 2014 by Alex Zhavoronkov and Alexander Aliper, it is best known for rentosertib (development code INS018_055, also written ISM001-055), an idiopathic-pulmonary-fibrosis candidate that Insilico describes as the first drug to reach Phase II with both an AI-discovered target and an AI-generated molecule.[1][6] On 30 December 2025 the company listed on the Main Board of the Hong Kong Stock Exchange under stock code 3696.HK, raising about HKD 2.28 billion (roughly USD 293 million) in what it called the largest Hong Kong biotechnology initial public offering of that year.[6][8] Insilico operates research and development sites across several regions, with a registered base in the Cayman Islands and major operations in Hong Kong, mainland China, the United States, and the United Arab Emirates. It is one of the most prominent companies in [AI drug discovery](/wiki/ai_drug_discovery), alongside firms such as [Recursion](/wiki/recursion_pharmaceuticals), [Isomorphic Labs](/wiki/isomorphic_labs), and [Exscientia](/wiki/exscientia).

## What is Insilico Medicine?

Insilico Medicine is a generative-AI drug-discovery company that combines [deep learning](/wiki/deep_learning) target identification, [generative chemistry](/wiki/generative_chemistry), and clinical-trial outcome prediction into a single software platform called Pharma.AI. The thesis is that AI can compress the slowest and most expensive steps of early drug development: choosing the right biological target and designing a novel molecule against it. The company self-describes rentosertib as delivering "the industry's first proof-of-concept clinical validation of AI-driven drug discovery," a claim that, while widely cited, refers to early Phase 2a data rather than a confirmed clinical benefit.[3]

## Who founded Insilico Medicine?

Insilico Medicine was established in 2014, originally based in Baltimore, United States.[17] Co-founder and chief executive Alex Zhavoronkov was born in Latvia, holds a master's degree in biotechnology from Johns Hopkins University and a doctorate from Moscow State University, and was active in aging and longevity research before turning to drug discovery.[17] Co-founder Alexander Aliper has served in scientific and leadership roles including president of the company. Early backing came from Deep Knowledge Ventures, and the company's initial focus was on aging biology and biomarkers before it concentrated on a broad therapeutic pipeline.

By the time of its 2025 listing, Insilico ran a dual co-chief-executive structure: Zhavoronkov leads artificial intelligence and corporate strategy, while Feng Ren, who joined in 2020 after eleven years working on small-molecule drugs at GlaxoSmithKline, leads drug discovery and development.[17] The company reported a research staff of roughly 249 people at the time of its IPO, the large majority of whom hold advanced degrees. Insilico also operates a related longevity venture and has historically positioned aging as a long-term scientific theme, though its commercial pipeline centers on fibrosis, oncology, immunology, and other established disease areas.

## How does the Pharma.AI platform work?

Insilico's core asset is Pharma.AI, an integrated software platform that the company updates on a roughly twice-yearly cadence. It combines several engines that span target discovery, chemistry, and clinical analysis. Pharma.AI draws on techniques from [deep learning](/wiki/deep_learning) and earlier work by the company on [generative adversarial networks](/wiki/generative_adversarial_network) and [reinforcement learning](/wiki/reinforcement_learning).

The main publicly named components are:

- **PandaOmics**, a target-discovery engine that ingests genomic, transcriptomic, and biomedical-text data to rank candidate disease targets. It was used to nominate TNIK as a target for fibrosis.
- **Chemistry42**, a [generative chemistry](/wiki/generative_chemistry) engine that designs novel small molecules predicted to bind a chosen target while optimizing for synthetic feasibility, novelty, and drug-like properties. It generates and prioritizes structures for synthesis and testing.
- **inClinico**, a clinical-trial outcome prediction tool. In a 2023 paper in *Clinical Pharmacology and Therapeutics*, Insilico researchers reported that the system achieved an area under the receiver operating characteristic curve of 0.88 in predicting Phase II to Phase III transitions on a quasi-prospective dataset, and they reported 79 percent accuracy on a smaller prospective set where outcomes could be measured.[16] These results are from the developer and have not yet been independently reproduced at scale.

The company has also described newer [foundation-model](/wiki/foundation_model) and multi-agent components, marketed under names such as Nach0 and a research-assistant agent. Insilico operates a robotics-equipped automated laboratory to run synthesis and assays, which it uses to feed experimental data back into its models.

An early and widely cited demonstration of the approach was a 2019 paper in *Nature Biotechnology*, in which a generative reinforcement-learning system the company called GENTRL designed novel inhibitors of the kinase DDR1; the company reported designing candidate molecules in 21 days and completing preclinical validation in mice within about 46 days total.[15] That work was a proof of concept rather than a clinical program, and it should not be conflated with the later rentosertib effort. The 2019 result, like much of the company's published validation, has drawn both interest and scrutiny over how much of the speedup was attributable to the AI itself versus the surrounding experimental infrastructure.

## What is rentosertib (INS018_055)?

Rentosertib is an oral small-molecule inhibitor of TNIK (TRAF2- and NCK-interacting kinase), developed for [idiopathic pulmonary fibrosis](/wiki/idiopathic_pulmonary_fibrosis), a progressive and often fatal scarring disease of the lungs. Insilico has stated that PandaOmics identified TNIK as the target and that Chemistry42 generated the molecule, and the company reports that the early discovery phase was completed in about 18 months with fewer than 80 molecules synthesized.[1] The drug received a generic name (rentosertib) from the World Health Organization, and the program has advanced through Phase I into Phase II.

The pivotal data point is a randomized Phase 2a trial, named GENESIS-IPF, whose results were published in *Nature Medicine* on 3 June 2025.[1] The published paper reports that the trial enrolled 71 patients across 21 sites in China, beginning 19 July 2023, and ran for 12 weeks.[1][2] (Several company press releases state 22 sites; the peer-reviewed paper states 21, so the published figure is used here.[1][3]) Patients were randomized to placebo (n=17), 30 mg once daily (n=18), 30 mg twice daily (n=18), or 60 mg once daily (n=18). The primary endpoint was safety and tolerability (the percentage of patients with at least one treatment-emergent adverse event), which the company reports was met.[1]

As an exploratory efficacy signal, the 60 mg once-daily arm showed a mean improvement in forced vital capacity (FVC) of +98.4 mL (95% confidence interval 10.9 to 185.9) over 12 weeks, compared with a mean decline of -20.3 mL (95% confidence interval -116.1 to 75.6) in the placebo arm.[1][2] The lead investigator, Professor Zuojun Xu of Peking Union Medical College, said: "Rentosertib represents a truly innovative therapeutic, with both its target identification and molecular design powered by AI, an approach that is pioneering in the pharmaceutical industry."[3] Founder and CEO Alex Zhavoronkov framed the result more cautiously, stating that the data "warrants further investigation in larger-scale clinical trials of longer duration."[3]

These efficacy numbers are exploratory and come from small arms, and several caveats are important and were acknowledged by the authors and independent coverage.[4][5] Seven of the patients on active drug discontinued because of liver injury or dysfunction (0 of 18 in the 30 mg once-daily arm, 4 of 18 in the 30 mg twice-daily arm, and 3 of 18 in the 60 mg once-daily arm), several of them while also taking the approved antifibrotic nintedanib, and only 12 of 18 patients (about 67 percent) completed the high-dose arm.[1][2] Quality-of-life measures were described as largely inconclusive owing to high variance between arms. The authors also noted the small per-arm sample size, the geographic and demographic homogeneity of an all-China cohort, and the short follow-up. A Phase 2a trial of this kind establishes early safety and a preliminary signal; it is not designed to confirm clinical benefit, which would require larger and longer Phase 3 testing. Insilico has reported progressing rentosertib toward later-stage development and has separately pursued an inhaled formulation that received clearance to begin a direct-to-lung clinical study.

## What is in Insilico's pipeline?

By its 2025 listing, Insilico reported more than 30 internally generated programs, of which around 10 had received investigational new drug (IND) clearance and roughly seven were in active clinical development. Oncology is the largest therapeutic area. The company has out-licensed several assets and signed discovery collaborations, with management citing aggregate deal values well above one billion US dollars across partnerships, though most of that headline value is contingent on future milestones that may never be paid.

| Program / asset | Target or area | Indication | Status / notable deal |
| --- | --- | --- | --- |
| Rentosertib (INS018_055 / ISM001-055) | TNIK inhibitor | Idiopathic pulmonary fibrosis | Phase 2a reported in *Nature Medicine*, June 2025; inhaled formulation in development |
| ISM3091 | USP1 inhibitor | Oncology (BRCA-mutant and related tumors) | Out-licensed to Exelixis (2023), about 80 million US dollars upfront plus milestones |
| ISM3312 | 3CLpro inhibitor | Coronavirus / antiviral | Clinical-stage oral antiviral |
| MEN2501 | Antibody-drug conjugate target | Oncology | Licensed to the Menarini Group and Stemline; deal value reported above 500 million US dollars; a 5 million US dollar milestone followed first-in-human dosing |
| Sanofi collaboration | Multiple targets | Multiple | Announced 2022; upfront and nomination fees up to about 21.5 million US dollars, with potential milestones cited up to roughly 1.2 billion US dollars plus royalties |
| Qilu Pharmaceutical collaboration | Cardiometabolic | Multiple | Drug-development collaboration reported near 120 million US dollars |

Other named partners over the company's history include Fosun Pharma and Saudi Aramco's venture arm. As with most early-stage biotech licensing, the very large totals quoted for these deals are biocontingent, meaning they depend on hitting development, regulatory, and sales milestones.

## How much funding has Insilico Medicine raised, and when did it IPO?

Insilico raised more than 400 million US dollars across private rounds from investors including Qiming Venture Partners, Warburg Pincus, and Prosperity7 Ventures (the venture arm of Saudi Aramco), among others. In March 2025 it announced a 110 million US dollar Series E round led by Value Partners Group.[10]

On 30 December 2025 the company listed on the Hong Kong Stock Exchange Main Board under the stock code 3696.HK. The offering priced at HKD 24.05 per share for about 94,690,500 shares and raised roughly HKD 2.28 billion (HKD 2.277 billion), equivalent to about 290 to 293 million US dollars, which the company and trade press described as Hong Kong's largest biotechnology IPO of 2025.[6][8] It was also reported as the first AI-driven biotech to list on the Main Board under the exchange's Chapter 8.05 route for pre-revenue technology companies.[6] Cornerstone investors reportedly included Eli Lilly, Tencent, and Temasek.[6] The Hong Kong public tranche was oversubscribed by roughly 1,427 times, and the stock opened at HKD 35.00 on debut, well above its HKD 24.05 offer price.[6] Founder and CEO Alex Zhavoronkov said: "With this massively oversubscribed listing we set several world's firsts further confirming Insilico's validated leadership position in AI-powered drug discovery."[6]

## How has Insilico Medicine been received?

Reception of Insilico has been a mix of enthusiasm and caution. Supporters point to rentosertib as the most concrete clinical evidence to date that an end-to-end AI workflow can produce a drug with a plausible efficacy signal in patients, and to the company's deep partnership roster. Skeptics note that the Phase 2a results rest on small arms in a single country, that the liver-related discontinuations warrant careful monitoring in larger trials, and that AI-originated compounds have so far cleared Phase 2 at roughly the same rate as conventional drugs, with several high-profile AI-led programs from other companies (for example Exscientia's EXS-21546 and BenevolentAI's BEN-2293) having failed. The broader question of how much credit belongs to the AI versus standard medicinal chemistry and trial execution remains debated. Insilico's place in [AI in healthcare](/wiki/ai_in_healthcare) is therefore widely cited as a leading test case rather than a settled validation, and its long-term significance will depend on Phase 3 outcomes and approvals that had not occurred as of mid-2026.

## References

1. Liu, J., et al. "A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial." *Nature Medicine*, 3 June 2025. https://www.nature.com/articles/s41591-025-03743-2
2. PMC mirror of the *Nature Medicine* phase 2a article (PMC12353801). https://pmc.ncbi.nlm.nih.gov/articles/PMC12353801/
3. Insilico Medicine. "Insilico Announces Nature Medicine Publication of Phase IIa Results of Rentosertib." Press release, June 2025. https://www.prnewswire.com/news-releases/insilico-medicine-announces-nature-medicine-publication-of-phase-iia-results-evaluating-rentosertib-the-novel-tnik-inhibitor-for-idiopathic-pulmonary-fibrosis-ipf-discovered-and-designed-with-a-pioneering-ai-approach-302472070.html
4. Drug Discovery Trends. "Insilico's rentosertib clears a phase 2a hurdle." 2025. https://www.drugdiscoverytrends.com/insilicos-ai-designed-rentosertib-shows-promise-in-first-phase-2a-trial-results/
5. AJMC. "AI-Derived Therapy for IPF Shows Potential in Phase 2a Trial." 2025. https://www.ajmc.com/view/ai-derived-therapy-for-ipf-shows-potential-in-phase-2a-trial
6. Insilico Medicine. "Insilico Medicine Lists on Hong Kong Stock Exchange ... 2025's Largest Hong Kong Biotech IPO." Press release, 30 December 2025. https://www.prnewswire.com/news-releases/insilico-medicine-lists-on-hong-kong-stock-exchange-showing-ai-drug-discovery-momentum-with-2025s-largest-hong-kong-biotech-ipo-302650606.html
7. Drug Discovery World. "Insilico Medicine becomes 2025's largest Hong Kong biotech IPO." 2026. https://www.ddw-online.com/insilico-medicine-becomes-2025s-largest-hong-kong-biotech-ipo-39723-202601/
8. Pharmaphorum. "Insilico ends 2025 with $293m Hong Kong IPO." 2025. https://pharmaphorum.com/news/insilico-ends-2025-293m-hong-kong-ipo
9. Longevity.Technology. "Insilico debuts on HK Stock Exchange, locking in more than $290m." 2025. https://longevity.technology/news/insilico-debuts-on-hk-stock-exchange-locking-in-more-than-290m/
10. Insilico Medicine. "Insilico Medicine Secures $110 Million Series E Financing." Press release, 13 March 2025. https://www.eurekalert.org/news-releases/1076658
11. Exelixis, Inc. "Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091." 2023. https://ir.exelixis.com/news-releases/news-release-details/exelixis-and-insilico-medicine-enter-exclusive-global-license
12. Pharmaphorum. "Insilico adds Sanofi to partnership roster with $888m deal." 2022. https://pharmaphorum.com/news/insilico-adds-sanofi-partnership-roster-888m-deal
13. Insilico Medicine. "Insilico Medicine Receives USD 5 Million Milestone Payment from Menarini Group ... MEN2501." Press release, 2025. https://www.prnewswire.com/news-releases/insilico-medicine-receives-usd-5million-milestone-payment-from-menarini-group-following-first-in-human-fih-achievement-for-men2501-302676790.html
14. Insilico Medicine. "Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration." Press release. https://insilico.com/news/ckvxca1tu1-insilico-medicine-and-qilu-pharmaceutica
15. Zhavoronkov, A., et al. "Deep learning enables rapid identification of potent DDR1 kinase inhibitors." *Nature Biotechnology*, 2019. https://www.nature.com/articles/s41587-019-0224-x
16. Aliper, A., et al. "Prediction of Clinical Trials Outcomes Based on Target Choice and Clinical Trial Design with Multi-Modal Artificial Intelligence." *Clinical Pharmacology and Therapeutics*, 2023. https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.3008
17. Alex Zhavoronkov, Wikipedia (biographical background). https://en.wikipedia.org/wiki/Alex_Zhavoronkov